All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Nucala (mepolizumab) wins European Commission approval for chronic obstructive pulmonary disease following Ph3 trial
Antibody, respiratory disease, monoclonal antibody, COPD, IL-5 target, eosinophilic phenotype - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly, Innovent Biologics partner on oncology immunology development, $350M upfront, $8.5B milestones
Co-development, oncology, immunology, milestone payments, royalties - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Priovant's brepocitinib (JAK1/TYK2 inhibitor) shows positive Ph2 results for cutaneous sarcoidosis, advancing to Ph3
Small molecule, autoimmune, JAK inhibitor, cutaneous sarcoidosis, TYK2 target - Read more

Genentech's fenebrutinib (fenebrutinib) shows superiority over Ocrevus in Ph3 trial for primary progressive multiple sclerosis
Small molecule, neurological, BTK inhibitor, multiple sclerosis, primary progressive multiple sclerosis - Read more

THE GOOD
Earnings & Finances

Biogen provides upbeat 2026 profit forecast despite mid-single-digit sales decline from MS product pressures
Monoclonal antibody, neurological, financial, strategic - Read more

THE GOOD
Fundraises

Agomab Therapeutics, SpyGlass Pharma collectively raise $350M IPOs, inflammatory/ophthalmic treatments
Autoimmune, small molecule, ophthalmology, drug delivery platform - Read more

THE GOOD
Mergers & Acquisitions

SVF Vaccines and Novakand Pharma enter reverse acquisition agreement valued at SEK 55 million ($6M)
Vaccine, strategic, major transaction, financial - Read more

THE GOOD
Regulatory

FDA grants priority review for Pfizer's HYMPAVZI (marstacimab) label expansion in hemophilia A or B patients
Antibody, hemophilia, monoclonal antibody, tissue factor pathway inhibitor, pediatric patients - Read more

FDA Commissioner Makary promises swift action against Hims' illegal compounded Wegovy pill following Novo Nordisk complaints
GLP-1 agonist, metabolic disease, regulatory, competitive - Read more

THE GOOD
Strategic Plans

Illumina shifts focus to healthcare customers amid NIH funding disruptions, expects 2026 revenue growth
DNA sequencing, oncology, strategic, revenue impact - Read more [Paywall]

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

UniQure pauses AMT-191 gene therapy dosing in Fabry disease Ph1/2 trial after liver toxicities
Gene therapy, rare disease, AAV gene therapy, Fabry disease, dose-limiting toxicity - Read more

THE BAD
Lawsuits

Medtronic hit with $382M antitrust damages for monopolizing surgical device market through exclusionary bundling practices
Medical device, competitive, major transaction, antitrust - Read more

HHS abandons 340B rebate pilot program after American Hospital Association wins legal challenge blocking implementation
Pharmaceutical pricing, safety-net hospitals, operational, financial - Read more

THE BAD
Layoffs

Roche's Genentech cut at least 489 jobs last year, new disclosure reveals additional layoffs
Biopharmaceuticals, operational, cost reduction, strategic - Read more

THE BAD
Regulatory

BridgeBio shares drop 15% after Pfizer's tafamidis patent revoked in Europe, threatening generic competition
Small molecule, cardiovascular, competitive, financial - Read more

THE BAD
Strategic Plans

Hims & Hers cancels compounded GLP-1 pill plans after FDA backlash and federal investigation threat
Peptide, obesity, regulatory, competitive - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here